CAY10602

CAY10602 is an activator of sirtuin 1 (SIRT1).¹ It inhibits LPS-induced TNF-α release in THP-1 cells when used at concentrations of 20 and 60 µM. CAY10602 (5 µM) decreases the expression of GPX4, SLC7A11, and SLC3A2, as well as increases the levels of iron and malondialdehyde (MDA), in A549 lung and MDA-MB-231 and Hs 578T breast cancer cells.² It reduces apoptosis and lipid accumulation induced by oleic acid (Item Nos. 90260 | 24659) in HepG2 cells when used at a concentration of 20 µM.³

WARNING This product is not for human or veterinary use.

1. Nayagam, V.M., Wang, X., Tan, Y.C., et al. SIRT1 modulating compounds from high-throughput screening as anti-inflammatory and insulin-sensitizing agents. J. Biomol. Screen. 11(8), 959-967 (2006).

2. Sui, S., Zhang, J., Xu, S., et al. Ferritinophagy is required for the induction of ferroptosis by the bromodomain protein BRD4 inhibitor (+)-JQ1 in cancer cells. Cell Death Dis. 10, 331 (2019).

3. Jiang, Y., Chen, D., Gong, Q., et al. Elucidation of SIRT-1/PGC-1α-associated mitochondrial dysfunction and autophagy in nonalcoholic fatty liver disease. Lipids Health Dis. 20(1), 40 (2021).